Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [798]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [798]

Deployment focused model for treatment development , 557

Depression

antepartum , 32

with atypical features , 6–7

brain abnormalities associated with , 26–27 , 61

with catatonic features , 6

chronic , 6 , 47

cognitive diathesis-stress model , 11–12

comorbidity

anxiety disorders , 9 , 36 , 37 , 170

substance use disorder , 9 , 37 , 409

double , 6

genetics , 24 , 25 t

geriatric , 32

help-seeking behavior for, perceived effectiveness , 535–36 , 536 t

hypothalamic-pituitary-adrenal axis hyperactivity , 25–26

interpersonal vulnerability , 15–17

major

age of onset , 4

cognitive vulnerability to , 11–12

combination therapy , 43 , 47–48

community attitudes toward , 533 , 534 t

comorbidity , 9

alcohol use disorders , 362

dysthymia , 6

eating disorders , 272 , 273 , 309

impact on treatment outcome , 36 , 37–38 , 46

diagnosis , 5–7 , 5 t

versus dysthymic disorder , 7 , 7 t

epidemiology , 7–17 , 70–71

family environment and , 9–10 , 15–17

family history and , 9

gender and , 9 , 27

interpersonal vulnerability , 15–17

personality/temperament and , 10–11

pharmacotherapy . See also Antidepressants

in adolescents , 43–47 , 45 t

in adults , 42–43

augmentation therapy , 43 , 46

combination therapy , 43

with psychotherapy , 47–48

prepubertal, versus adolescent-onset , 4 , 7

prevention programs , 61–67

future directions and recommendations , 66–67

indicated , 62–63

research agenda , 72–73

selective , 64–66

universal , 64

psychosocial therapy

in adults , 30–34

in children and adolescents , 34–42

with pharmacotherapy , 47–48

preventive , 38 , 62–65

pubertal status and , 7

rates , 7–9 , 8 f

recurrence , 4 , 70

relationship to schizophrenia , 102

research agenda , 70–73

risk factors , 9–10 , 59–61 , 70

sequelae to , 4 , 56

stress and , 12–15 , 24–25

subtypes , 67

treatment research agenda , 71–72

maternal

and offspring depression , 9 , 10 , 16–17

and response to cognitive-behavioral therapy , 36 , 36 f, 37

with melancholic features , 6

parental, and offspring depression , 9 , 10 , 16–17 , 65–66

pharmacotherapy . See Antidepressants

postpartum , 6 , 32

postpsychotic , 126

primary care physician findings , 583 , 584 t, 586 , 586t–588 t, 587 , 591 t

rates , 7–9 , 8 f, 9 f

relapse prevention , 33

schizophrenia and , 102 , 126

school professional findings , 601 , 602 t

self-propagating nature , 526

specific vulnerability hypothesis , 14–15

stress and , 12–15

subsyndromal

cognitive-behavioral therapy for , 38

as risk factor for major depression , 59–60

treatment-resistant , 43

Detoxification , 403–4

Development

brain, during adolescence , xxix–xxxi, 85–86 , 87 f, 175–76

youth

applications , 501–2

ecological approach , 501

positive . See Positive youth development

problem-centered approach , 500–501

Developmental assets, in positive youth development , 502

Developmental group therapy, for suicidal youth , 480 t, 481

Developmental milestones, in schizophrenia, premorbid abnormalities , 137–38 , 138 f, 139 f, 149

Dextroamphetamine dependence , 349–53 . See also Stimulant abuse

Diagnostic and Statistical Manual for Primary Care (DSM-PC), eating disorders criteria , 263

Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria

end p.798